Why a focal cartilage injury in the knee rarely heals itself

The short answer is that knee cartilage has no blood supply of its own. Every other tissue in the body calls on the bloodstream to deliver repair cells — platelets, white cells, growth factors — to an injury site. Articular cartilage relies instead on slow diffusion of nutrients from the surrounding synovial fluid, which means the inflammatory cascade that would normally patch damaged tissue simply never arrives at a chondral defect. The chondrocytes embedded in the matrix are largely isolated, and their capacity to replicate and rebuild is extremely limited even in healthy cartilage.

When the knee sustains a direct blow, a twisting load, or a high-impact compression — the kinds of forces seen in sports injuries, falls, or road-traffic incidents — the mechanical disruption goes beyond tearing the cartilage surface. Impact loading alters chondrocyte metabolism and changes the water content of the extracellular matrix, setting off a slow process of progressive tissue loss that the joint cannot arrest on its own.

Defect size, depth, and location all influence how quickly this deterioration unfolds and what can be done about it. Full-thickness lesions and those covering 2 cm² or more are associated with a higher risk of accelerated progression to knee osteoarthritis — a process in which the exposed subchondral bone gradually loses its protective surface, joint space narrows, and pain and stiffness become chronic. Smaller or partial-thickness defects carry lower but still meaningful risk if left untreated and symptomatic.

This biological reality — rather than any procedural preference — is the reason clinicians generally recommend active intervention for symptomatic focal cartilage lesions rather than a prolonged period of watchful waiting.

What ChondroFiller Liquid Cartilage is and how it works

ChondroFiller® liquid — also branded as Liquid Cartilage™ — is a CE-marked Class III medical device, the highest regulatory risk category for implantable devices in Europe and the same classification applied to products such as joint replacements. That designation requires rigorous pre-market clinical evaluation before the product can be used in practice. The device is composed of acid-extracted, murine-derived Type I collagen: a highly purified protein solution that, once placed inside the cartilage defect under ultrasound guidance, polymerises rapidly to form a stable gel that sits within and conforms to the lesion.

The gel itself contains no donor cells — there is no tissue bank, no laboratory culture process, and no second procedure to retrieve harvested material. Instead, the collagen matrix works through a principle called acellular matrix-induced chondrogenesis. Think of it as a temporary scaffolding erected inside the defect: the structure provides both a physical framework and chemical signals that draw the patient's own progenitor cells — from the surrounding synovium and subchondral bone — into the site. Once there, those recruited cells are guided to differentiate into cartilage-repair tissue. As that process unfolds over weeks to months, the collagen scaffold gradually degrades and is replaced by the body's own regenerating tissue.

Because everything happens in a single outpatient appointment with no cell harvest and no return visit for implantation, the pathway is meaningfully simpler than conventional cell-based approaches.

How ChondroFiller is delivered as an outpatient injection

Attending an appointment for ChondroFiller® liquid does not involve a theatre booking, surgical incisions, or arthroscopic portals. The collagen scaffold is placed using ultrasound-guided intra-articular injection, allowing the clinician to visualise the defect site in real time and position the material accurately within it. Local anaesthetic is applied beforehand to minimise discomfort during placement, and the procedure is carried out entirely in an outpatient setting.

Most patients return home the same day. Because there is no surgical wound, no general anaesthetic, and no post-operative immobilisation of the kind associated with arthroscopic or open procedures, the early recovery profile is considerably lighter than conventional cartilage surgery. Activity guidance following the injection is tailored to individual circumstances and agreed at consultation, but the broad aim is a graduated return to normal loading as the scaffold settles and cellular recruitment begins.

Follow-up MRI — using MOCART scoring to assess defect filling and repair-tissue integration — is typically used to track structural progress over the months that follow. It is this longitudinal imaging that has provided objective evidence of how the scaffold matures, and that data underpins the clinical outcomes reviewed in the next section.

What the clinical evidence shows for knee outcomes

Published data from four clinical studies of focal knee cartilage defects show a consistent improvement of approximately 30 points on the International Knee Documentation Committee (IKDC) score — a validated patient-reported measure of knee pain, function, and activity. To give that number context: the minimum clinically important difference (MCID) for the IKDC is 16.7 points, the threshold below which most patients cannot perceive a meaningful change in their knee. A 30-point gain sits well above that threshold and represents a substantial shift in day-to-day function.

The most robust single-study result comes from Jerosch et al., a prospective post-market clinical follow-up (PMCF) study in which patients achieved a mean IKDC improvement of 32.4 points — and, importantly, that improvement was sustained and marginally increased at three-year follow-up, with participants reaching an absolute IKDC score of 80. That durability out to three years is clinically relevant, because earlier cartilage repair techniques often show functional decline over a similar timeframe.

MRI assessments using MOCART scoring provide an objective structural counterpart to those patient-reported gains. MOCART evaluates how completely a defect has been filled and how well the repair tissue integrates with the surrounding native cartilage; a score above 80 is generally interpreted as sound structural repair. European knee cohorts treated with ChondroFiller® averaged MOCART scores of 81.6 to 84.3 at one year. Longitudinal MRI data also confirm the gradual maturation trajectory noted in the previous section: a mean of 65.3 at four weeks rising to 81.6 at twelve months, consistent with ongoing collagen remodelling rather than immediate static fill.

On safety, the reported complication rate across published cohorts is approximately 0% and the reoperation rate is 3–8%. These results come from manufacturer-sponsored prospective studies; no independent randomised controlled trial comparing ChondroFiller® directly with microfracture or ACI has been completed to date. The data are promising, but that evidence limitation is worth noting when forming expectations.

How ChondroFiller compares with microfracture and ACI

Three treatments dominate the conversation when a focal post-traumatic cartilage defect is identified: microfracture, autologous chondrocyte implantation (ACI/MACI), and injectable scaffold therapy such as ChondroFiller® liquid. Each has a different procedural burden, a different defect-size envelope, and a different tissue outcome — and those differences matter when weighing options.

| | Microfracture | ACI / MACI | ChondroFiller® liquid | |---|---|---|---| | Stages required | 1 (surgical) | 2 (harvest + implant) | 1 (outpatient injection) | | Defect size limit | <2–4 cm² | Up to ~8 cm² | Up to 6 cm² | | Tissue type produced | Fibrocartilage | Hyaline-like | Hyaline-like | | Complication rate | Low | Up to 17% | ~0% | | Reoperation rate | Up to 41% | Up to 37% | ~3–8% |

Microfracture remains one of the most widely performed cartilage procedures and is well-suited to smaller lesions in appropriate patients. Its limitation is that the fibrocartilage it produces is biomechanically weaker than native hyaline cartilage, and functional outcomes in some series decline over time — particularly for defects approaching or exceeding 3 cm². The SUMMIT trial and MACI data indicate that lesions of 3 cm² or larger tend to achieve superior function and pain relief with advanced scaffold-based approaches compared with microfracture alone.

ACI and MACI produce higher-quality repair tissue and carry strong long-term data, but the two-stage surgical process — a cell-harvest arthroscopy followed months later by implantation — represents a considerable commitment for patients, alongside the higher complication and reoperation figures shown above.

ChondroFiller® liquid offers a single-stage injectable pathway that avoids theatre admission and produces hyaline-like repair tissue across a defect-size range that extends beyond what microfracture can reliably address. That said, no randomised controlled trial has yet compared ChondroFiller® directly with either microfracture or ACI/MACI head to head; the comparative figures above reflect published cohort data and should be interpreted with that in mind. Microfracture and ACI remain established pathways with appropriate indications, and the right choice for any individual patient depends on defect size, grade, and clinical context — something a consultant assessment will determine.

Who is a suitable candidate and next steps at Lincolnshire Knee

The patient most likely to benefit from ChondroFiller® liquid is someone with a known focal cartilage injury — a discrete area of damage resulting from a sporting incident, a fall, a twisting injury, or a direct blow to the knee — rather than the generalised background wear of diffuse osteoarthritis. Where articular cartilage has worn away broadly across the joint, a targeted scaffold approach is not the appropriate pathway.

Defect size and depth are among the key variables that determine suitability. The published studies reviewed in this article have evaluated lesions up to 6 cm²; very large or diffuse cartilage loss falls outside that range and will typically require a different treatment strategy. The overall health of the surrounding joint — including meniscal integrity and limb alignment — also informs whether this option is appropriate for a given patient. Self-selection is not reliable here: a formal assessment is essential.

At Lincolnshire Knee, assessment begins with clinical review and is supported by detailed knee MRI evaluation. The clinic uses onMRI™, an AI-driven MRI analysis platform that includes cartilage segmentation and T2 mapping, which can characterise defect size and depth with a level of precision useful for treatment planning. Where biomechanical factors such as gait loading pattern appear relevant, objective assessment is available to complete the picture.

Lincolnshire Knee is part of the MSK Doctors group and accepts patients without a GP referral. Clinics are available at Sleaford (NG34) and Grantham (NG31). To arrange a consultant assessment, visit lincolnshireknee.co.uk.